COMMUNIQUÉS West-GlobeNewswire

InspireMD Reports Second Quarter 2025 Financial Results
05/08/2025
--- Management to host investor conference call today, August 5 th , at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the [...]
IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update
05/08/2025
Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for [...]
Izotropic’s IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers
05/08/2025
- Global breast imaging market projected to reach $8.69 billion by 2030, with IzoView addressing key clinical and commercial trends driving demand - Company positioned to lead in dense breast imaging, where rising [...]
Vireo Growth Inc. to Release Second Quarter 2025 Results on August 13, 2025
05/08/2025
MINNEAPOLIS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its second fiscal quarter ended June [...]
CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference
05/08/2025
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will [...]
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
05/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies [...]
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
05/08/2025
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases ( [...]
electroCore Appoints James C. Theofilos to the Board of Directors
05/08/2025
ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board [...]
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
05/08/2025
Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025 Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913 All three clinical programs (CRB-701, CRB-913, CRB-601 [...]
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
05/08/2025
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug [...]
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
05/08/2025
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI- [...]
Envision Pharma Group appoints Tom Langan as Chief Executive Officer
05/08/2025
Envision Pharma Group appoints Tom Langan as Chief Executive Officer Leading industry executive with 30 years’ of experience providing technology-enabled solutions to life sciences companies Fairfield, Connecticut, USA [...]
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
05/08/2025
SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
05/08/2025
FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical [...]
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
05/08/2025
Second -quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 million As of June 30, 2025 , more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, 2045 Announced [...]
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
05/08/2025
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in [...]
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
05/08/2025
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents [...]
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
05/08/2025
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE [...]
CorVel Announces Revenues and Earnings
05/08/2025
FORT WORTH, Texas, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended June 30, 2025. Revenues for the quarter were $235 million, an increase from $212 million [...]

Pages